Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B |
| Cost of revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B |
| Gross profit | $9.25B | $8.07B | $8.41B | $8.79B | $8.90B | $8.17B | $7.53B | $8.94B |
| Gross margin | 71.3% | 70.2% | 67.2% | 71.9% | 72.5% | 72.9% | 61.0% | 75.1% |
| Research and development | $2.96B | $2.74B | $3.98B | $3.16B | $2.58B | $2.45B | $3.22B | $2.64B |
| Selling, general and administrative | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B |
| Operating expenses | $5.22B | $4.80B | $6.99B | $5.78B | $6.63B | $4.86B | $7.05B | $7.03B |
| Operating income | $4.03B | $3.27B | $1.42B | $3.01B | $2.27B | $3.31B | $480.00M | $1.91B |
| Operating margin | 31.0% | 28.5% | 11.4% | 24.6% | 18.5% | 29.5% | 3.9% | 16.1% |
| EBITDA | $4.62B | $3.87B | $2.40B | $4.02B | $4.79B | $4.32B | $2.36B | $4.50B |
| Interest income | $101.00M | $0 | $0 | — | $139.00M | $0 | $0 | — |
| Interest expense | −$407.00M | $0 | $0 | — | −$485.00M | $0 | $0 | — |
| Income before taxes | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175.00M | $1.68B |
| Income taxes | $770.00M | $561.00M | $384.00M | $919.00M | $460.00M | $509.00M | $99.00M | $461.00M |
| Net income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $76.00M | $1.22B |
| Net margin | 25.6% | 23.3% | 8.7% | 18.0% | 10.7% | 22.0% | 0.6% | 10.2% |
| EPS, basic | $1.62 | $1.31 | $0.53 | $1.08 | $0.64 | $1.21 | $0.04 | $0.60 |
| EPS, diluted | $1.62 | $1.31 | $0.53 | $1.08 | $0.64 | $1.20 | $0.04 | $0.60 |
| Diluted shares | 2.05B | 2.05B | 2.04B | 2.04B | 2.04B | 2.04B | 2.03B | 2.03B |
Figures describe Bristol-Myers Squibb shares, not any token. As of Jul 30, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.